Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : License symbols : Pfe save search
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
Published: 2024-01-09 (Crawled : 12:00) - globenewswire.com
GNMSF | $281.02 3.83% 210
|
Health Technology
|
| O: -3.69%
H: 1.71%
C: -2.41%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.07%
H: 0.88%
C: -0.68%
GMAB | $28.32 -0.74% -0.74% 240K
|
Health Technology
|
| O: -1.1%
H: 0.46%
C: -0.06%
tivdak drug license review food cancer application
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2023-11-30 (Crawled : 22:00) - prnewswire.com
ALPMF | $9.594 43.47% 2.2K
|
Health Technology
|
| O: 3.87%
H: 0.0%
C: 0.0%
ALPMY | $9.46 -1.11% 500K
|
Manufacturing
|
| O: -3.37%
H: 4.51%
C: 4.51%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -4.92%
H: 1.48%
C: -0.21%
padcev fda license review bladder cancer treatment application grants
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children
Published: 2023-01-06 (Crawled : 17:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.64%
H: 3.24%
C: 1.88%
fda children vaccine application license review pneumococcal
U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults
Published: 2022-12-07 (Crawled : 12:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.08%
H: 2.81%
C: 0.98%
fda candidate disease vaccine application respiratory license virus review
Voyager Therapeutics Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target
Published: 2022-10-04 (Crawled : 11:00) - ir.voyagertherapeutics.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.25%
H: 1.33%
C: 0.47%
VYGR | $7.55 -2.46% -2.52% 1M
|
Health Technology
|
| O: 6.57%
H: 13.17%
C: 10.17%
rare disease license therapeutics
Everest Medicines' Licensing Partner Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-Class Profile in Ulcerative Colitis
Published: 2022-05-24 (Crawled : 12:20) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: 0.0%
license potential ulcerative colitis
Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential
Published: 2022-03-29 (Crawled : 01:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 1.35%
H: 0.15%
C: -2.33%
trial potential positive results topline license phase 3 ulcerative colitis
Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential
Published: 2022-03-30 (Crawled : 01:00) - prnewswire.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.87%
H: 0.98%
C: -1.43%
trial potential positive results topline license phase 3 ulcerative colitis
Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries
Published: 2021-11-16 (Crawled : 12:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.56%
H: 0.0%
C: 0.0%
covid treatment antiviral patent license
Voyager Therapeutics Announces License Option Agreement with Pfizer for Next-Generation TRACERᵀᴹ AAV Capsids to Enable Neurologic and Cardiovascular Gene Therapy Programs
Published: 2021-10-06 (Crawled : 12:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.61%
H: 0.33%
C: -0.1%
VYGR | $7.55 -2.46% -2.52% 1M
|
Health Technology
|
| O: 61.54%
H: 3.26%
C: -3.01%
cardiovascular gene therapy therapy license cardio aav9 gene therapies aav capsids
ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals
Published: 2021-09-28 (Crawled : 12:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -1.15%
H: 0.49%
C: -0.07%
potential license hiv
Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency
Published: 2021-09-24 (Crawled : 21:00) - globenewswire.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
| Email alert
Add to watchlist
OPK | $1.235 -1.2% -1.21% 4.1M
|
Health Technology
| Email alert
Add to watchlist
fda growth hormone license growth hormone application
Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY® in Individuals 16 and Older
Published: 2021-08-25 (Crawled : 17:00) - globenewswire.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.7%
H: 0.5%
C: -1.1%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.71%
H: 0.37%
C: 0.08%
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
|
| O: -2.02%
H: 4.37%
C: 4.23%
fda license submission comirnaty® order
Everest Medicines Announces that Spero Therapeutics Entered into Licensing Agreement with Pfizer Inc. for SPR206 in ex-U.S. and ex-Asia Territories
Published: 2021-07-05 (Crawled : 11:00) - prnewswire.com
SPRO | $1.48 -1.33% -1.35% 240K
|
Health Technology
| Email alert
Add to watchlist
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
| Email alert
Add to watchlist
license
Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206
Published: 2021-06-30 (Crawled : 23:00) - globenewswire.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.03%
H: 1.17%
C: 1.0%
SPRO | $1.48 -1.33% -1.35% 240K
|
Health Technology
|
| O: 19.27%
H: 2.94%
C: -1.56%
license
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of "ultra-long-acting" medicines for HIV
Published: 2021-06-22 (Crawled : 07:00) - prnewswire.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.03%
H: 0.71%
C: 0.51%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.7%
H: 0.05%
C: -1.06%
HALO M | $37.84 -0.47% -0.48% 790K
|
Health Technology
|
| O: 0.19%
H: 2.15%
C: 1.89%
collaboration drug license technology drug delivery liver hiv
Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of their COVID-19 Vaccine
Published: 2021-05-07 (Crawled : 11:00) - globenewswire.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.36%
H: 2.09%
C: 1.36%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.92%
H: 0.88%
C: 0.66%
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
|
| O: 9.13%
H: 1.36%
C: 0.2%
covid fda fda approval vaccine license approval submission application
Celcuity Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Gedatolisib, a First-in-Class PI3K/mTOR Inhibitor for Breast Cancer
Published: 2021-04-08 (Crawled : 21:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.14%
H: 0.53%
C: 0.0%
CELC | $16.4 -3.59% -3.72% 200K
|
Commercial Services
|
| O: -1.04%
H: 0.42%
C: 0.42%
cancer breast cancer commercialization license
Pyxis Oncology Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Multiple Antibody-Drug Conjugates
Published: 2021-03-18 (Crawled : 17:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.73%
H: 1.24%
C: 0.68%
antibody drug commercialization license
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.